Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | SUFU |
| Gene Name: | SUFU |
| Protein Full Name: | Suppressor of fused homolog |
| Alias: | PRO1280; SUFUH; SUFUXL; suppressor of fused; suppressor of fused homolog (Drosophila) |
| Mass (Da): | 53947 |
| Number AA: | 484 |
| UniProt ID: | Q9UMX1 |
| Locus ID: | 51684 |
| COSMIC ID: | SUFU |
| Gene location on chromosome: | 10q24.32 |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | LOSS |
| Effect of active protein on cancer: | INHIBIT |
| Number of cancer specimens: | 20997 |
| Percent of cancer specimens with mutations: | 0.46 |
| Mutations observed as inherited: | NA |
| Found in amplified chromosomal regions in human cancers: | NA |
| Deregulated in translocations: | NA |
| Deregulated by viral insertion: | NA |
| Transduced into viral genome: | NA |
| Gene undergoes hypermethylation: | NA |
| Normal role description: | SUFU is a negative regulator of the hedgehog pathway, a cascade implicated in proliferation, and downregulates GLI1-mediated transactivation of target genes by targeting it for degradation. It is also a negative regulator of beta-catenin signalling. Defects in SUFU has been associated with medulloblastoma, a malignant invasive embryonal tumour of the cerebellum. |